Myasthenia Gravis

A rapid-tapering prednisone regimen was found to be feasible, well-tolerated and associated with good outcomes in patients with moderate to severe generalized myasthenia gravis, according to findings published in JAMA Neurology.

A 45-year-old woman was admitted to the neurology service at Lahey Hospital and Medical Center with symptoms of double vision, gait disturbance secondary to lower extremity weakness and subjective memory loss.

Eculizumab, which is only approved by the FDA for the treatment of three rare conditions, may be used frequently for off-label indications that lack strong scientific evidence, according to a study published in JAMA Internal Medicine.